Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Has announcements × mCRPC × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 26 Breast Neoplasms 14 Neoplasms 13 Neoplasm Metastasis 8 Ovarian Neoplasms 7 Leukemia, Lymphocytic, Chronic, B-Cell 7 Small Cell Lung Carcinoma 6 Multiple Myeloma 6 Melanoma 6 Colorectal Neoplasms 6 Carcinoma, Renal Cell 6 Urinary Bladder Neoplasms 5 Thyroid Cancer, Papillary 5 Recurrence 5 Lymphoma, Non-Hodgkin 5 Head and Neck Neoplasms 5 Urothelial Cancer 4 Thyroid Neoplasms 4 Sarcoma 4 Prostatic Neoplasms 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Lung Neoplasms 4 Endometrial Neoplasms 4 Colonic Neoplasms 4 Salivary Gland Neoplasms 3 Pancreatic Neoplasms 3 Neurofibromatosis 1 3 Neurofibroma, Plexiform 3 Neuroendocrine Tumors 3 Lymphoma, Follicular 3

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡